CN102811730B - 孕激素作为糖皮质激素增敏剂的使用 - Google Patents

孕激素作为糖皮质激素增敏剂的使用 Download PDF

Info

Publication number
CN102811730B
CN102811730B CN201180005214.2A CN201180005214A CN102811730B CN 102811730 B CN102811730 B CN 102811730B CN 201180005214 A CN201180005214 A CN 201180005214A CN 102811730 B CN102811730 B CN 102811730B
Authority
CN
China
Prior art keywords
glucocorticoid
corticosteroid
insensitivity
dexamethasone
progesterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180005214.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102811730A (zh
Inventor
杜涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Eglin Pharmaceutical Co Ltd
Original Assignee
PRAIRIE PHARMACEUTICALS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PRAIRIE PHARMACEUTICALS LLC filed Critical PRAIRIE PHARMACEUTICALS LLC
Publication of CN102811730A publication Critical patent/CN102811730A/zh
Application granted granted Critical
Publication of CN102811730B publication Critical patent/CN102811730B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
CN201180005214.2A 2010-02-08 2011-02-07 孕激素作为糖皮质激素增敏剂的使用 Active CN102811730B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30232510P 2010-02-08 2010-02-08
US61/302,325 2010-02-08
US13/021,950 US10231976B2 (en) 2010-02-08 2011-02-07 Methods for the use of progestogen as a glucocorticoid sensitizer
US13/021,950 2011-02-07
PCT/US2011/023917 WO2011097571A2 (en) 2010-02-08 2011-02-07 Methods for the use of progestogen as a glucocorticoid sensitizer

Publications (2)

Publication Number Publication Date
CN102811730A CN102811730A (zh) 2012-12-05
CN102811730B true CN102811730B (zh) 2014-07-09

Family

ID=44353892

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180005214.2A Active CN102811730B (zh) 2010-02-08 2011-02-07 孕激素作为糖皮质激素增敏剂的使用

Country Status (8)

Country Link
US (1) US10231976B2 (enExample)
EP (2) EP3689364A1 (enExample)
JP (1) JP5913136B2 (enExample)
CN (1) CN102811730B (enExample)
BR (1) BR112012019725A2 (enExample)
ES (1) ES2773079T3 (enExample)
RU (1) RU2016101363A (enExample)
WO (1) WO2011097571A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
RU2016101363A (ru) 2010-02-08 2018-11-21 Прэари Фармасьютикалз, Ллк Способ лечения заболеваний, связанных с глюкокортикоидной нечувствительностью
US10987361B2 (en) * 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
US10993879B2 (en) * 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US20160008376A1 (en) * 2014-07-10 2016-01-14 Biocopea Limited Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders
US9624998B2 (en) 2014-07-30 2017-04-18 Tenneco Automotive Operating Company Inc. Electromagnetic flywheel damper and method therefor
KR20170044203A (ko) * 2014-09-03 2017-04-24 리젠 파마슈티컬스 소시에떼 아노님 이중 pi3k 델타-감마 키나제 억제제 및 코르티코스테로이드를 포함하는 조성물 및 치료방법
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017053416A1 (en) * 2015-09-21 2017-03-30 Prairie Pharmaceuticals LLC Treating auto-immune and auto-inflammatory diseases
CN106994128A (zh) * 2016-01-26 2017-08-01 上海普瑞得生物技术有限公司 17-α羟孕酮化合物在预防和治疗中性粒细胞炎症疾病中的应用
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CN106310280A (zh) * 2016-08-18 2017-01-11 滨州医学院 地瑞那韦增强糖皮质激素抗炎作用的医药新用途
JP7595413B2 (ja) 2016-11-30 2024-12-06 ケース ウエスタン リザーブ ユニバーシティ １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
WO2018145080A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CN108272804A (zh) * 2018-02-09 2018-07-13 上海礼璞生物医药科技有限公司 孕激素在制备糖原合成酶激酶-3β抑制剂药物中的应用及糖原合成酶激酶-3β抑制剂
CN108159057A (zh) * 2018-02-09 2018-06-15 上海礼璞生物医药科技有限公司 黄体酮及其药学上可接受的衍生物在制备抑制α平滑肌肌动蛋白表达的药物中的用途
CN108159056A (zh) * 2018-02-09 2018-06-15 上海礼璞生物医药科技有限公司 孕激素在制备组蛋白去乙酰化酶抑制剂和气道周围胶原沉积抑制剂药物中的应用及抑制剂
PE20212246A1 (es) 2018-11-21 2021-11-24 Univ Case Western Reserve Composiciones y metodos para modular la actividad de deshidrogenasas de cadena corta
KR102490714B1 (ko) * 2018-12-28 2023-01-26 재단법인 아산사회복지재단 Pibf 단백질을 유효성분으로 함유하는 염증성 질환 예방 또는 치료용 약학 조성물
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition
CN113559107B (zh) * 2020-04-28 2023-01-06 深圳埃格林医药有限公司 孕激素在制备抑制细胞因子风暴的药物中的应用
CN113616660A (zh) * 2020-05-07 2021-11-09 深圳埃格林医药有限公司 孕激素制剂及其用途
CN114569623A (zh) * 2020-12-01 2022-06-03 深圳埃格林医药有限公司 己酸羟孕酮在制备治疗间质性肺炎的药物中的用途
EP4209219A1 (en) * 2022-01-07 2023-07-12 MetrioPharm AG Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione
CN115501236B (zh) * 2022-11-09 2024-01-23 复旦大学附属肿瘤医院 一种醋酸烯诺孕酮在制备降低肺部炎症性疾病的药物中的应用
CN118924767B (zh) * 2024-07-25 2025-11-11 中南大学湘雅医院 孕烯醇酮作为活性成分在制备银屑病或特应性皮炎的治疗药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US4720489A (en) * 1984-10-15 1988-01-19 Douglas Shander Hair growth modification with ornithine decarboxylase inhibitors
AU763307B2 (en) * 1998-02-04 2003-07-17 Charlotte-Mecklenburg Hospital Authority Androsterone derivatives for inhibiting DNA binding of AP-1 and airway smooth muscle proliferation
US6562370B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US20010034340A1 (en) * 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
SK288222B6 (sk) * 2000-12-14 2014-09-04 Ortho-Mcneil Pharmaceutical, Inc. Steroidné hormonálne prípravky a spôsoby ich prípravy
FR2821555B1 (fr) * 2001-03-01 2003-05-16 Besins Int Lab Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations
JP2005511211A (ja) 2001-12-05 2005-04-28 ニュファームクス， エルエルシー ヘリオックスを用いるエアロゾル化した薬物の吸入のための医療デバイスおよび方法
CA2483005A1 (en) * 2002-04-26 2003-11-06 Pfizer Health Ab Treatment of metabolic syndrome
US20060216231A1 (en) * 2002-09-23 2006-09-28 Shelley Carl S Methods for diagnosing and treating tumors and suppressing cd promoters
DE10251028A1 (de) * 2002-11-01 2004-05-19 Jenapharm Gmbh & Co. Kg Verwendung von Progesteron oder einem Progesteronrezeptor-Agonisten zur Hemmung der Steroidsynthese
FR2851918B1 (fr) * 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
JP4898431B2 (ja) * 2003-04-29 2012-03-14 ザ ジェネラル ホスピタル コーポレイション 複数薬物の持続放出のための方法およびデバイス
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
AU2005235369B2 (en) * 2004-04-22 2010-11-11 Acucort Ab Pharmaceutical compositions for acute glucocorticoid therapy
US20060052306A1 (en) 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
EP1773344A1 (en) * 2004-07-07 2007-04-18 Wyeth a Corporation of the State of Delaware Cyclic progestin regimens and kits
GB0425266D0 (en) 2004-11-16 2004-12-15 Norton Healthcare Ltd Pharmaceutical manufacturing process
ATE499104T1 (de) 2005-03-24 2011-03-15 Univ Emory Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns
AU2006249349B2 (en) * 2005-05-26 2012-01-12 Teva Women's Health, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
JP2009519972A (ja) 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経肺投与または経鼻投与用製薬の製造方法
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
RU2016101363A (ru) 2010-02-08 2018-11-21 Прэари Фармасьютикалз, Ллк Способ лечения заболеваний, связанных с глюкокортикоидной нечувствительностью
US20110262502A1 (en) 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
PT105058B (pt) 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos

Also Published As

Publication number Publication date
US20110195031A1 (en) 2011-08-11
US10231976B2 (en) 2019-03-19
EP2533799B1 (en) 2019-11-20
ES2773079T3 (es) 2020-07-09
WO2011097571A2 (en) 2011-08-11
WO2011097571A3 (en) 2011-12-29
RU2012135985A (ru) 2014-03-20
RU2016101363A3 (enExample) 2018-11-21
BR112012019725A2 (pt) 2020-11-10
EP2533799A4 (en) 2013-07-31
EP3689364A1 (en) 2020-08-05
JP2013518908A (ja) 2013-05-23
EP2533799A2 (en) 2012-12-19
EP2533799B8 (en) 2019-12-25
RU2016101363A (ru) 2018-11-21
CN102811730A (zh) 2012-12-05
JP5913136B2 (ja) 2016-04-27

Similar Documents

Publication Publication Date Title
CN102811730B (zh) 孕激素作为糖皮质激素增敏剂的使用
CN103582484B (zh) 17-己酸羟孕酮(17-hpc)的肺部递送
JP2013518908A5 (enExample)
Brazzini et al. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use
Fiala et al. Review of medical abortion using mifepristone in combination with a prostaglandin analogue
US20150182539A1 (en) Pregnancy hormone combination for treatment of autoimmune diseases
JP2009102412A (ja) 糖質コルチコイドレセプター特異的アンタゴニストを使用するストレス障害を処置するための方法
JP2009102343A (ja) ダウン症候群を有する成人において認知低下を阻害する方法
Guerra et al. Progestins in combined contraceptives
Feiteiro et al. Genomic and nongenomic effects of mifepristone at the cardiovascular level: a review
EP2026818B1 (en) Combination of steroids having transporter-enhanced corticosteroid activity
Albuquerque et al. A randomized comparative trial of a combined oral contraceptive and azelaic acid to assess their effect on sleep quality in adult female acne patients
HK40038111A (en) Methods for the use of progestogen as a glucocorticoid sensitizer
Sitruk-Ware Hormone therapy and the cardiovascular system: the critical role of progestins
Renold et al. Biological effects of fluorinated derivatives of hydrocortisone and progesterone in man
RU2575824C2 (ru) Способы применения прогестогена в качестве глюкокортикоидного сенсибилизатора
JP3895490B2 (ja) Ａｐ−１のｄｎａ結合及び気道平滑筋増殖を阻害するアンドステロン誘導体
AU2005307151B2 (en) Gaba-steroid antagonists and their use for the treatment of CNS disorders
WO2003045362A2 (en) Treatment of th1 dominated immunological disease states with non-endogenous gestagen compounds
Papapetrou et al. Cortisol Secretion in Nelson Syndrome: Persistence After Total Adrenalectomy for Cushing Syndrome
Battipaglia et al. The hormonal contraceptive choice in women with polycystic ovary syndrome and metabolic syndrome
Bissell et al. Glucocorticoids
Kovačič Cognitive effects of hormone replacement therapy in menopausal women
Fluticasone 21 CH2OH CH2OH CH2OH
Call Treatment of Adrenocorticosteroid Disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20191125

Address after: 14a, Shuntian building, No. 62, guimiao Road, Lifang community, Nanshan street, Nanshan District, Shenzhen City, Guangdong Province

Patentee after: Shenzhen Eglin Pharmaceutical Co., Ltd

Address before: 12209 bisano street, 20878 North Potomac, MD, USA

Co-patentee before: PRAIRIE PHARMACEUTICALS LLC

Patentee before: Du Tao

TR01 Transfer of patent right